

DR. JEROME PREMMEREUR: BIOGRAPHY

Dr. Jerome Premmereur is Chief Executive Officer and President of the TB Alliance. Dr. Premmereur has nearly two decades of experience overseeing the development of new medicines for a variety of indications, including infectious and cardiovascular diseases. He is the former Head of Medical Affairs (US Pharmaceuticals Operations) and Vice President of Medical Risk Management for sanofi-aventis, as well as former Senior Vice President of Aventis Global Medical Affairs.

As a veteran pharmaceutical executive, Dr. Premmereur has significant international regulatory expertise and knowledge of the registration path for new drugs in at least 60 countries. At sanofi-aventis, he managed a team of more than 500, bringing lifesaving treatments to registration, worldwide, and coordinating groups involved in running clinical trials, filing regulatory applications, conducting health economics research, and producing medical communications.

A native of France, Dr. Premmereur has focused much of his career on the development of treatments for cancer, as well as cardiovascular, infectious, and metabolic diseases. After board certification in cardiology in 1983, he practiced as a cardiologist, working primarily in the intensive care units of several French hospitals. In addition to running a private practice in Argenteuil, France, he worked in consultation at Paris' Hospital Cochin.

In 1991, Dr. Premmereur joined Rhône-Poulenc Rorer, based in Paris, where he helped develop and bring to market numerous pharmaceutical products. Notably, he was appointed to lead the worldwide development and broad international registration of Clexane/Lovenox (enoxaparin), an anticoagulant now approved by the FDA for eight indications.

Following the success of Clexane/Lovenox, Dr. Premmereur was appointed head of Global Medical Affairs. He was responsible for managing large trials in oncology, anti-infectives, and hormone replacement therapy, as well as cardiovascular, allergic and CNS diseases. After the December 1999 merger with Hoechst Marion Roussel to create Aventis, Dr. Premmereur led the development of products in the areas of diabetes, osteoporosis, oncology, anti-infectives, and cardiovascular, respiratory, allergic, and CNS diseases.

Dr. Premmereur has authored and co-authored studies published in leading medical journals, including the New England Journal of Medicine and the Journal of the American College of Cardiology. He is a long-time member of the Fellowship of the American College of Cardiology, the French Medical Order, and Societe Française de Cardiologie. He received his MD from the College/University Paris Medical School in 1981.

<http://www.tballiance.org/about/team.php>